- Home
- CSCI vs APM Comparison
CSCI vs APM Comparison
Compare CSCI & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSCI
- APM
- Stock Information
- Founded
- CSCI 1990
- APM 2010
- Country
- CSCI Canada
- APM United Kingdom
- Employees
- CSCI N/A
- APM N/A
- Industry
- CSCI
- APM Biotechnology: Pharmaceutical Preparations
- Sector
- CSCI
- APM Health Care
- Exchange
- CSCI NYSE
- APM Nasdaq
- Market Cap
- CSCI 11.1M
- APM 9.8M
- IPO Year
- CSCI 1996
- APM 2018
- Fundamental
- Price
- CSCI $3.14
- APM $1.11
- Analyst Decision
- CSCI
- APM
- Analyst Count
- CSCI 0
- APM 0
- Target Price
- CSCI N/A
- APM N/A
- AVG Volume (30 Days)
- CSCI 5.3K
- APM 25.7K
- Earning Date
- CSCI 11-12-2024
- APM 12-20-2024
- Dividend Yield
- CSCI N/A
- APM N/A
- EPS Growth
- CSCI N/A
- APM N/A
- EPS
- CSCI N/A
- APM N/A
- Revenue
- CSCI $4,834,000.00
- APM $431,378.00
- Revenue This Year
- CSCI N/A
- APM $157,729.10
- Revenue Next Year
- CSCI N/A
- APM N/A
- P/E Ratio
- CSCI N/A
- APM N/A
- Revenue Growth
- CSCI N/A
- APM N/A
- 52 Week Low
- CSCI $2.81
- APM $1.09
- 52 Week High
- CSCI $11.10
- APM $17.49
- Technical
- Relative Strength Index (RSI)
- CSCI N/A
- APM 27.13
- Support Level
- CSCI N/A
- APM $1.21
- Resistance Level
- CSCI N/A
- APM $1.37
- Average True Range (ATR)
- CSCI 0.00
- APM 0.10
- MACD
- CSCI 0.00
- APM 0.00
- Stochastic Oscillator
- CSCI 0.00
- APM 4.44
About CSCI COSCIENS BIOPHARMA INC
Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for healthcare and cosmetics industries. The company is engaged in the development of therapeutic assets and proprietary extraction technology.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.